Glenmark to directly commercialise Ryaltris in US, expanding innovative portfolio

Glenmark will directly commercialise RYALTRIS nasal spray in the US from April 1 2026 to strengthen its allergy portfolio, shares fell 1.7 percent to 2095.50 rupees

Leave a Reply

Your email address will not be published. Required fields are marked *